GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » EPS (Diluted)

Mural Oncology (Mural Oncology) EPS (Diluted) : $-11.62 (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology EPS (Diluted)?

Mural Oncology's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.84. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.62.

Mural Oncology's EPS (Basic) for the three months ended in Mar. 2024 was $-1.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.62.

Mural Oncology's EPS without NRI for the three months ended in Mar. 2024 was $-1.84. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.62.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Mural Oncology EPS (Diluted) Historical Data

The historical data trend for Mural Oncology's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology EPS (Diluted) Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
EPS (Diluted)
-10.51 -11.37 -12.43

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only -2.78 -3.14 -3.07 -3.57 -1.84

Competitive Comparison of Mural Oncology's EPS (Diluted)

For the Biotechnology subindustry, Mural Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mural Oncology's PE Ratio falls into.



Mural Oncology EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Mural Oncology's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-207.447-0)/16.690
=-12.43

Mural Oncology's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-30.917-0)/16.794
=-1.84

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mural Oncology EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Mural Oncology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines